Support Centre
26 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
AttraX® Putty in spinal fusion
DOI 10.1186/ISRCTN38726728
ClinicalTrials.gov identifier
EudraCT number
Public title AttraX® Putty in spinal fusion
Scientific title AttraX® Putty in spinal interbody fusion: Evaluation of radiographic and clinical outcomes
Acronym NUVA.AX1101
Serial number at source NUVA.AX1101
Study hypothesis 1. To evaluate the fusion rate following the use of AttraX®Putty in spinal fusion procedures performed at one or two contiguous level(s) of the cervical and lumbar spine.
2. To evaluate the complication rate associated with the use of AttraX®Putty compared to published and/or retrospective data for autograft, allograft, synthetics, bone morphogenic protein (BMP), or other graft alternatives.
3. To evaluate and identify any relationships between clinical outcomes (pain and function) and radiographic outcomes (fusion rate)
Lay summary Lay summary under review 3
Ethics approval Not provided at time of registration
Study design Prospective non-randomized multi-arm observational study
Countries of recruitment Germany, United Kingdom
Disease/condition/study domain Degenerative conditions of the lumbar and cervical spine
Participants - inclusion criteria 1. Persistent arm pain unresponsive to conservative treatment for at least 6 weeks or persistent back and/or leg pain unresponsive to conservative treatment for at least 6 months, unless surgical treatment is clinically indicated sooner
2. Indicated for anterior cervical discectomy and fusion (ACDF), anterior lumbar interbody fusion (ALIF or XLIF), or posterior lumbar interbody fusion (PLIF or TLIF) at one or two contiguous motion segments (C3 to T1 in the cervical spine or L1 to S1 in the lumbar spine)
3. Objective evidence of primary diagnosis must be confirmed by appropriate imaging studies
4. 18-70 years of age at the date of written informed consent
5. Able to undergo surgery based on physical exam, medical history and surgeon judgment
6. Expected to survive at least 2 years beyond surgery
7. Willing and able to return for post-treatment exams according to the follow-up called for in the protocol
8. Signed and dated informed consent form
Participants - exclusion criteria 1. Mental or physical condition that would limit the ability to comply with study requirements
2. Previous failed fusion at any spinal level
3. Prior fusion procedure at operative level(s) (i.e. no revision of prior level)
4. Prior instrumented fusion at level(s) adjacent to operative level(s)
5. Systemic or local infection; active or latent
6. Diseases that significantly inhibit bone healing (e.g., osteoporosis, metabolic bone disease)
7. Treatment with pharmaceuticals interfering with calcium metabolism
8. Undergoing chemotherapy or radiation treatment
9. Chronic use of steroids (defined as more than 6 weeks of steroid use within 12 months of surgery, other than episodic use or inhaled corticosteroids)
10. Involvement in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested)
11. Significant general illness [e.g., human immunodeficiency virus (HIV), active metastatic cancer of any type, uncontrolled diabetes, dialysis dependent renal failure, symptomatic liver disease]
12. Immunocompromised or is being treated with immunosuppressive agents
13. Pregnant, or plans to become pregnant during the study
14. A prisoner
15. Participating in another clinical study that would confound study data
Anticipated start date 01/12/2011
Anticipated end date 01/12/2013
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 150
Interventions 1. Study Arm: Anterior Approach Cervical Interbody Fusion(ACDF)
ACDF with CoRoent® Small Contoured or Small Lordotic Plus (SLP) and AttraX® Putty in the interbody space, and with NuVasive Helix ACPTM
2. Study Arm: Anterior Approach Lumbar Interbody Fusion
eXtreme Lateral Interbody Fusion (XLIF) using CoRoent XL or Anterior Lateral Interbody Fusion (ALIF) using BrigadeTM or XLR implant(s) and AttraX® Putty in the interbody space, and with bilateral posterior stabilization by Armada® or SpheRx® pedicle screw system.
3. Study Arm: Posterior Approach Lumbar Interbody Fusion
Bilateral or unilateral Posterior Lumbar Interbody Fusion (PLIF) or Transforaminal Lumbar Interbody Fusion (TLIF) using CoRoent Large or Large Oblique (LO) implant(s) (respectively) and AttraX® Putty in the interbody space, and with bilateral posterior stabilization by Armada or SpheRx pedicle screw system.
All postoperative restrictions and rehabilitation of the subject are per the Investigator’s standard of care.
Primary outcome measure(s) The radiographic fusion rates at 12 months and 24 months
Secondary outcome measure(s) 1. The complication rate attributable to the use of AttraX® Putty
2. The evaluation of angular displacement on flexion / extension films at the 6-, 12-, and 24-month follow-up visits
3. The evaluation of bridging bone on computerised tomography (CT) at 12- and 24-month (as required) follow-up visits
4. Preservation of interverterbal disc height over time
5. The change in American Spinal Injury Association (ASIA) score from baseline at each follow-up visit
6. The change in subject self-reported pain scores Visual Analogue Scale (VAS) from baseline at each follow-up visit
7. The change in Neck Disability Index (NDI) or Oswestry Disability Index (ODI) scores from baseline at each follow-up visit
8. The change in SF-36 scores from baseline at each follow-up visit
9. Patient satisfaction at each follow-up visit
10. The number of subjects returning to employment and the mean time of return to employment (as applicable)
Sources of funding NuVasive, Inc. (USA)
Trial website
Contact name Ms  Kelli  Howell
  Address 7475 Lusk Blvd
  City/town San Diego
  Zip/Postcode 92121
  Country United States of America
Sponsor NuVasive, Inc. (USA)
  Address c/o Rebecca Smith
Manager, Clinical Resources
7475 Lusk Blvd
  City/town San Diego
  Zip/Postcode 02141
  Country United States of America
Date applied 28/11/2011
Last edited 20/06/2012
Date ISRCTN assigned 15/12/2011
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.